• Home
  • NEW DAY MEDICINE
  • 3 (27) 2019
  • 20 -3 (27/1) 2019 — Daminov B.T., Ubaydullaeva B.N. — INFORMATIVITY OF THE HEMOGRAM IN PATIENTS RECEIVING PROGRAM HEMODIALYSIS

20 -3 (27/1) 2019 — Daminov B.T., Ubaydullaeva B.N. — INFORMATIVITY OF THE HEMOGRAM IN PATIENTS RECEIVING PROGRAM HEMODIALYSIS

INFORMATIVITY OF THE HEMOGRAM IN PATIENTS RECEIVING PROGRAM HEMODIALYSIS

Daminov B.T., Tashkent Pediatric Medical Institute.

Ubaydullaeva B.N. Tashkent Pediatric Medical Institute.

Resume,

The aim of the study was to anemia in рatients with terminal chronic kidney disease on ргодгат hemodialysis to determine the frequency of occurrence of various рathogenetic variants.

The study included 120 рatients with CKD V receiving рrogram hemodialysis. All рatients routinely with anti- anemic goal was orally administered iron рreрaration 1 tablet once a day and EPPS (recombinant erythroрoietin- beta) 50 lU/kg in with each hemodialysis.

Patients were examined for the presence of anemia. Sampling of venous blood with definition of common analysis evaluated the concentration of serum iron, ferritin, and transfer in a reference values laboratory use data obtained in a cohort of healthy volunteers with in a 95% confidence interval.

The study demonstrated that 72.5% of patients with HCBP during the therapy with oral iron preparations and recombinant erythropoietin observed persistence of anemia. Pathogenetic mechanisms of resistance to EPS were: cofactor deficiency (57.47%); iron deficiency (24.14%), while in 11.49% of patients – functional; anabolic deficiency (18.39%); hemolytic anemia (14.94%); chronic activation of systemic inflammation (14.94%); aplastic anemia (3.45%).

Given the increase in cardiovascular and cancer risk in patients with HCBP on the background of high doses of EPS, an individual hemogram analysis is needed to identify mechanisms of resistance to EPS and their compensation, which will improve the therapy of anemia in this group of patients.

Keywords: program hemodialysis, renal anemia, erythropoietin resistance, cofactor deficiency, iron deficiency, hemolytic anemia, anabolic deficiency, anemia against chronic inflammation, aplastic anemia

First page

85

Last page

90

For citation: Daminov B.T., Ubaydullaeva B.N. Informativity of the hemogram in patients receiving program hemodialysis//New Day in Medicine 3(27)2019 85-90 https://cutt.ly/AbxTvky

List of References

  1. Abensur H. Anemia da doen?a renal cr?nica. //J Bras Nefrol. 2004; 26(3): 26-28.
  2. Brugnara C. Iron deficiency and erythropoiesis: new diagnostic approaches. // Clin Chem. 2003; 49(10):1573-1578.
  3. Brugnara C., Laufer M.R., Friedman A.J., Bridges K., Plat O. Reticulocyte hemoglobin content (CHr): early indicator of iron deficiency and response to ^гару. //Blood. 1994; 83(10): 3100­3101.
  4. Fishbane S., Shapiro W., Dutka P., Valenzuela O.F., Faubert J. A randomized trial of iron deficiency testing strategies in hemodialysis patients.//Kidney Int. 2001; 60(6): 2406-2411.
  5. Hutchinson F.N., Jones W.J. A cost-effectiveness analysis of anemia screening before e^h^oie^ in patients with endstage renal disease.//Am J Kidney Dis. 1997; 29(5): 651-657.
  6. Kazmi W.H., Kausz A.T., Khan S., Abichandani R., Ruthazer R., Obrador G.T. Anemia: an early complication of chronic renal insufficiency.//Am J Kidney Dis. 2001; 38(4): 803-812.
  7. KDIGO clinical ртай^ guideline for anemia in chronic kidney disease. //Kidney Int S^L 2012; 2: 279-335
  8. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 ^date of hemoglobin target. //Am J Kidney Dis. 2007; 50(3): 471­530.
  9. Locatelli F., Aljama P., Barany P., Canaud B., Carrera F., Eckardt K.U. Revised European best р^й^ guidelines for the management of anaemia in patients with chronic renal failure. // №рЬго1 Dial Тишр^С 2004; 19(8ирр1. 2):ii1-ii47.
  10. Locatelli F., Covic A., Eckardt K.U., Wiecek A., Vanholder R., ERA-EDTA ERBP Advisory Board Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). //^рйго1 Dial Тишр^т. 2009; 24(2): 348-354.
  11. Locatelli F., Pisoni R.L., Combe C., Bommer J., Andreucci V.E., Piera L. Anaemia in hemodialysis patients of five Em^ean countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS).//Nephrol Dial ТгашркШ. 2004; 19(1): 121-132.
  12. Macdougall I.C., Hutton R.D., Coles G.A., William J.D. The use of erythropoietin in renal failure.// Postgrad Med J. 1991; 67(783): 9-15.
  13. Mast A.E., Blinder M.A., Dietzen D.J. Reticulocyte hemoglobin content. //Am J Hematol. 2008; 83(4): 307-310.
  14. McClellan, W., Aronoff, S.L., Bolton, W.K. et al. The prevalence of anemia in patients with chronic kidney disease.//Curr Med Res Орт. 2004; 20: 1501-1510.
  15. Mittman N., Sreedhara R., Mushnick R., Chattopadhyay J., Zelmanovic D., Vaseghi M. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO. // Am J Kidney Dis. 1997; 30(6): 912-922.
  16. National Kidney Foundation K/DOQI clinical ртай^ guidelines and clinical ртай^ recommendations for anemia in chronic kidney disease. // Am J Kidney Dis. 2006; 26(Suppl. 3):1-145.
  17. Ribeiro-Alves M.A., Gordan P.A. Diagn?stico de Anemia em Pacientes Portadores de Doen?a Renal Cr?nica. //J Bras Nefrol. 2014; 36(1 ЗиррЕ 1): 9-12.
  18. Saran, R., Li, Y., Robinson, B. et al. US Renal Data System 2015 annual data report: epidemiology of kidney disease in the United States. // (Svii, S1-Svii, 305)Am J Kidney Dis. 2016; 67
  19. Sesso R.C., Lopes A.A., Thome F.S., Lugon J.R., Watanabe Y., Santos D.R. Relat?rio do Censo Brasileiro de Di?lise 2012. //J Bras Nefrol. 2014; 36(1): 48-53.
  20. Stauffer, M.E. and Fan, T. Prevalence of anemia in chronic kidney disease in the United States.// PLoS One. 2014; 9: e84943

file

download